PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
503.87 - 512.55
344.79 - 555.45
23.62M / 20.39M (Avg.)
37.30 | 13.67
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
-2.27%
Negative net income growth while CRWD stands at 9.79%. Joel Greenblatt would see a comparative disadvantage in bottom-line performance.
-7.53%
Negative yoy D&A while CRWD is 8.01%. Joel Greenblatt would note a short-term EPS advantage unless competitor invests for future advantage.
19.19%
Some yoy growth while CRWD is negative at -556.47%. John Neff would see competitor possibly managing deferrals more aggressively for short-term advantage.
9.07%
SBC growth well above CRWD's 9.69%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-1449.42%
Both reduce yoy usage, with CRWD at -260.97%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-142.59%
Both yoy AR lines negative, with CRWD at -72.17%. Martin Whitman would suspect an overall sector lean approach or softer demand.
290.62%
Inventory growth of 290.62% while CRWD is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
204.59%
A yoy AP increase while CRWD is negative at -226.09%. John Neff would see competitor possibly improving relationships or liquidity more rapidly.
39.10%
Growth well above CRWD's 22.30%. Michael Burry would see a potential hidden liquidity or overhead issue overshadowing competitor's approach.
880.80%
Some yoy increase while CRWD is negative at -61.99%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
-34.78%
Both yoy CFO lines are negative, with CRWD at -14.77%. Martin Whitman would suspect cyclical or cost factors harming the entire niche’s cash generation.
-5.90%
Negative yoy CapEx while CRWD is 34.75%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
24.01%
Less M&A spending yoy vs. CRWD's 99.99%, reducing near-term risk. David Dodd would confirm the firm is not missing out on a strategic deal that competitor might exploit.
-26.54%
Negative yoy purchasing while CRWD stands at 0.84%. Joel Greenblatt sees a near-term liquidity advantage unless competitor’s new investments produce outsized returns.
25.80%
We have some liquidation growth while CRWD is negative at -99.51%. John Neff notes a short-term liquidity advantage if competitor is holding or restricted.
98.25%
We have some outflow growth while CRWD is negative at -2283.58%. John Neff sees competitor possibly pulling back more aggressively from minor expansions or intangible invests.
7.16%
We have mild expansions while CRWD is negative at -8.48%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
100.00%
Debt repayment growth of 100.00% while CRWD is zero at 0.00%. Bruce Berkowitz sees a mild advantage that can reduce interest costs unless expansions demand capital here.
-63.74%
Negative yoy issuance while CRWD is 6915.80%. Joel Greenblatt sees a near-term advantage in avoiding dilution unless competitor invests more effectively with the new shares.
-21.40%
We cut yoy buybacks while CRWD is 0.00%. Joel Greenblatt would question if competitor is gaining a per-share edge unless expansions justify holding cash here.